Walleye Capital
BNTC icon

Walleye Capital’s Benitec Biopharma BNTC Stock Holding History

Walleye Capital’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,705
Closed -$45.3K – 4341
2023
Q1 		$45.3K Sell
12,705
-7,531
-37% -$30.7K ﹤0.01% 3231
2022
Q4 		$58.5K Buy
20,236
+9,020
+80% +$30.6K ﹤0.01% 2492
2022
Q3 		$71K Buy
+11,216
New +$143K ﹤0.01% 2516

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's BNTC Position: Q2 2023 in Review

Walleye Capital sold out of Benitec Biopharma (BNTC) in Q2 2023, closing a stake of 12,705 shares — an estimated $45.3K sold.

Walleye Capital first reported a position in BNTC in Q3 2022 and held it in 3 quarters. The position peaked at $71K in Q3 2022. 17 funds tracked by Wall St. Rank hold BNTC as of Q2 2023.

  • Walleye Capital reported no remaining Benitec Biopharma position as of Q2 2023 after selling out during the quarter.
  • Walleye Capital sold 12,705 Benitec Biopharma shares in Q2 2023, an estimated $45.3K.
  • Walleye Capital first reported a position in Benitec Biopharma in Q3 2022 and held it in 3 quarters.
  • Walleye Capital's Benitec Biopharma position peaked at $71K in Q3 2022.
  • 17 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.